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Monitoring treatment: How often?
Although recommendations for how often to 
monitor bone mineral density (BMD) after 
initiating treatment vary, the consensus has 
been that periodic monitoring is useful. But 
there have been no randomized trials evalu-
ating BMD testing in patients taking bisphos-
phonates. 
Th e use of DXA scans to identify osteo-
porosis has been shown to be a cost-eff ective 
strategy in women older than 65 years,5  but 
there has not been a cost/benefi t analysis of 
follow-up DXA scanning after initiating treat-
ment. Th e cost of a scan ranges from about 
$150 to $300, and it is not known how many 
patients undergo repeat DXA scanning after 
starting treatment. 
STUDY SUMMARY
Yearly scans are not helpful
Th e study we report on here is a secondary 
analysis of data from the Fracture Interven-
tion Trial (FIT).6  In 1993, FIT randomized 
6457 US women ages 55 to 80 years with low 
hip bone density to either alendronate or 
placebo.  Th e initial dose of alendronate was 
5 mg/d, but was later increased to 10 mg/d 
when other studies found that the higher 
dose was more eff ective. FIT showed that 
alendronate increased BMD and decreased 
the risk of vertebral fracture.7  
Bell et al1 used a mixed-model statistical 
analysis to compare “within-person varia-
Bisphosphonate therapy: 
When not to monitor BMD
Monitoring bone density within the fi rst 3 years of 
therapy does not provide useful information—and it is 
costly besides. 
PRACTICE CHANGER
After starting patients on bisphosphonates 
for osteoporosis, wait at least 3 years before 
ordering a repeat dual-energy x-ray absorpti-
ometry (DXA) scan.1 
STRENGTH OF RECOMMENDATION
C: Based on a secondary analysis of a large 
randomized controlled trial. 
Bell KL, Hayen A, Macaskill P, et al. Value of routine monitoring of bone 
mineral density after starting bisphosphonate treatment: secondary 
analysis of treatment data. BMJ. 2009;338:b2266. 
ILLUSTRATIVE CASE
CASE  } Ms. K, a 68-year-old woman diag-
nosed with osteoporosis on a screening DXA 
scan a year ago, has been taking a bisphos-
phonate ever since. She’s anxious to know 
whether the medication is working and asks 
if it’s time for a repeat DXA scan. What should 
you tell her? 
Fragility fractures from osteoporosis are common in postmenopausal women. In the year 2000 alone, an estimated 
9 million such fractures occurred worldwide.2 
Treatment with bisphosphonates has been 
found to reduce the risk of fragility fractures,3 
and the United States Preventive Services Task 
Force (USPSTF) recommends a DXA scan to 
screen for osteoporosis in women older than 
65 years and some younger women at in-
creased risk.4 
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nate. Th is study advises us that it 
is not necessary to recheck BMD 
for at least 3 years after starting 
treatment. Elimination of early 
repeat DXA testing could result 
in signifi cant cost savings.
CAVEATS
Findings contradict usual 
recommendations
Physicians should be aware that the conclu-
sion of this study is not in line with recom-
mendations from a number of prominent 
organizations. Th e American Association of 
Clinical Endocrinology,9 the National Osteo-
porosis Foundation,10 and the North American 
Menopause Society11 all recommend follow-
up DXA testing in 1 or 2 years. 
❚ High-risk patient exception. Th e delay 
in repeat DXA testing may not be appropriate 
for patients at higher risk of bone density loss. 
However, a separate analysis of higher-risk 
groups was not done.  
Finally, while the fi ndings of Bell et al 
suggest that we should wait at least 3 years 
before retesting, it is still not clear whether 
there is any benefi t to repeat DXA testing at 
any interval, given the nearly universal re-
sponse rate. It is also possible that advances 
in DXA technology will reduce some of the 
variation in BMD results. 
CHALLENGES TO IMPLEMENTATION
Anxious patients
Patients like Ms. K may ask their physicians 
to retest well before 3 years. Yet those who 
undergo scanning after a shorter interval 
may be discouraged by early results. Advis-
ing patients that the treatment is almost uni-
formly eff ective in increasing BMD should 
reassure them that sticking with treatment is 
worthwhile.                   
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tion” in BMD (variation in DXA 
results over time in individuals) 
and “between-person variation” 
in BMD (variation in DXA results 
over time in the population of 
patients). Th e BMD of all FIT par-
ticipants in both the control and treatment 
groups was measured at baseline and at the 
1-, 2-, and 3-year marks.  Each individual was 
always tested on the same scanner to mini-
mize diff erences in machinery. 
❚ Individual results vary from year to 
year. Th e researchers found that the within-
person variation was about 10 times greater 
than the between-person variation. Th is fi nd-
ing suggests that the precision of DXA scan 
measurements is not that reliable from 1 test 
to another. 
The average annual increase in BMD 
in patients in the alendronate group was 
0.0085 g/cm2—which is smaller than the 
typical year-to-year (within-person) varia-
tion of 0.013 g/cm2. It would therefore be 
difficult to differentiate the medication’s ef-
fect from the random variation inherent in 
DXA scans.
❚ Response is favorable after 3 years 
of treatment. While there is variation in 
test results from year to year, longer-term 
fi ndings are more reliable. After 3 years of 
treatment, 97.5% of patients taking alendro-
nate had an increase in hip BMD of at least 
0.019 g/cm2, with a strong correlation be-
tween hip and spine measurements.  Al-
though this represents a relatively small 
change in Z and T scores, this increase in hip 
BMD is considered a favorable response that 
warrants continued treatment. Th ese fi nd-
ings are consistent with a previous analy-
sis of BMD monitoring in women taking 
bisphosphonates, in which those who had 
the largest drop in BMD after the fi rst year of 
treatment typically had a large gain over the 
second year.8
WHAT’S NEW
Now we know early testing 
is unnecessary
Not many studies are available to provide 
guidance about the interval between BMD 
measurements after starting a bisphospho-
INSTANT 
POLL 
QUESTION
How long do you 
typically wait 
after initiating 
bisphosphonate 
therapy before 
ordering a repeat 
DXA scan? 
• 1 year 
• 2 years
• ≥3 years
•  It depends on the 
patient. 
• Other_____
Go to jfponline.com
and take our instant poll 
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